- Joined
- Sep 20, 2016
- Messages
- 1,802
- Reaction score
- 502
http://www.clinicalpainadvisor.com/...pJobID=1021614898&spReportId=MTAyMTYxNDg5OAS2
"
The primary outcome measure was pain scores (assessed using the visual analog scale [VAS)]) changes from baseline at 6 months. Although both injections led to improvements in VAS pain scores, the improvements were more significant in patients receiving Hya-Joint Plus vs Synvisc-One: 34.2 mm, 34.6 mm, and 33.3 mm vs 19.9 mm, 22.8 mm, and 23.4 mm at 1, 3, and 6 months, respectively, with adjusted mean differences of -12.0 (P =.001), -8.5 (P =.033), and -6.6 (P =.045), respectively.
The secondary outcome measures, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Lequesne index for knee osteoarthritis severity, timed up and go test (TUG), single-limb stance (SLS), use of rescue analgesics, and patient satisfaction, were comparable between injection groups. However, those receiving Hya-Joint Plus demonstrated a small but statistically significant improvement in WOMAC stiffness subscale scores at 6 months (1.7 ± 1.2 vs 2.3 ± 1.7 for Synvisc-One; P =.043).
Although TUG time did not change significantly in either group, and both showed significant improvements in SLS time, there was some indication that patients with poor physical activity might derive greater benefit from Hya-Joint Plus. “We found that patients with an initial poor performance on the TUG test (>18.8 s) could benefit more, with regard to their performance at 3 months post-injection, if they were treated with Hya-Joint Plus. Similarly, patients with an initial poor performance on the SLS test could benefit more, with regard to their performance at 1 and 3 months, if they were treated with Hya-Joint Plus,” the researchers wrote. They were unsure of the mechanism behind this finding, but suspected a volume effect of Synvisc-One might cause excessive capsular distension, affecting patients' physical activity."
Any thoughts on this?
"
The primary outcome measure was pain scores (assessed using the visual analog scale [VAS)]) changes from baseline at 6 months. Although both injections led to improvements in VAS pain scores, the improvements were more significant in patients receiving Hya-Joint Plus vs Synvisc-One: 34.2 mm, 34.6 mm, and 33.3 mm vs 19.9 mm, 22.8 mm, and 23.4 mm at 1, 3, and 6 months, respectively, with adjusted mean differences of -12.0 (P =.001), -8.5 (P =.033), and -6.6 (P =.045), respectively.
The secondary outcome measures, including the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Lequesne index for knee osteoarthritis severity, timed up and go test (TUG), single-limb stance (SLS), use of rescue analgesics, and patient satisfaction, were comparable between injection groups. However, those receiving Hya-Joint Plus demonstrated a small but statistically significant improvement in WOMAC stiffness subscale scores at 6 months (1.7 ± 1.2 vs 2.3 ± 1.7 for Synvisc-One; P =.043).
Although TUG time did not change significantly in either group, and both showed significant improvements in SLS time, there was some indication that patients with poor physical activity might derive greater benefit from Hya-Joint Plus. “We found that patients with an initial poor performance on the TUG test (>18.8 s) could benefit more, with regard to their performance at 3 months post-injection, if they were treated with Hya-Joint Plus. Similarly, patients with an initial poor performance on the SLS test could benefit more, with regard to their performance at 1 and 3 months, if they were treated with Hya-Joint Plus,” the researchers wrote. They were unsure of the mechanism behind this finding, but suspected a volume effect of Synvisc-One might cause excessive capsular distension, affecting patients' physical activity."
Any thoughts on this?
